Status:
COMPLETED
Genome Expression in Lymphoma, Leukemia and Multiple Myeloma
Lead Sponsor:
National Cancer Institute (NCI)
Collaborating Sponsors:
Lymphoma/Leukemia Molecular Profiling Project (LLMPP)
Conditions:
Leukemia
Multiple Myeloma
Eligibility:
All Genders
1+ years
Brief Summary
This study will use genomics-based technology, such as DNA microarrays, to more precisely diagnose subsets of lymphoma, leukemia and multiple myeloma patients. There have been many attempts to classif...
Detailed Description
Current diagnosis of the lymphoid malignancies relies upon the morphological appearance of the cancer cells supplemented by a few molecular markers. Within a diagnostic category, the clinical courses ...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Diagnosis of lymphoid malignancy at one of the LLMPP participating institutions, including specimens originating at other clinical sites and submitted to LLMPP participating sites or National Cancer Center Singapore.
- Informed consent for research studies performed on biopsy material or waiver of the requirement for informed consent by the clinical research review boards at the LLMPP institutions or National Cancer Center Singapore.
- Sufficient frozen biopsy and/or FFPE material from initial biopsy and/or biopsies at relapse of disease to obtain adequate RNA and DNA for gene expression profiling and analysis of genomic alterations in the malignant cells.
Exclusion
Key Trial Info
Start Date :
November 9 2001
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
1340 Patients enrolled
Trial Details
Trial ID
NCT00339963
Start Date
November 9 2001
Last Update
January 8 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Institute (NCI), 9000 Rockville Pike
Bethesda, Maryland, United States, 20892